Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes
OBJECTIVE: Interleukin 1-beta (IL-1beta) is a major inflammatory cytokine. Blockade of the IL-1beta pathway is therapeutically efficacious in type 2 diabetes, but the mechanistic effects on the immune system are incompletely understood
Bibliographische Detailangaben
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 136(2010), 2 vom: 01. Aug., Seite 170-3
|
|---|
| 1. Verfasser: |
Sanda, Srinath
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Bollyky, Jenna,
Standifer, Nathan,
Nepom, Gerald,
Hamerman, Jessica A,
Greenbaum, Carla |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2010
|
|---|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.)
|
|---|
| Schlagworte: | Journal Article
Research Support, Non-U.S. Gov't
CD11b Antigen
Hypoglycemic Agents
ITGAM protein, human
Interleukin 1 Receptor Antagonist Protein
Interleukin-1beta
Interleukin-8 |
|---|